Rubedo Life Sciences Reports Positive Phase 1 Results for Anti-Aging Drug RLS-1496
Rubedo Life Sciences has announced promising early results from its first human clinical trial of RLS-1496, a senotherapeutic drug targeting aged cells linked to skin aging and related diseases. The four-week European trial demonstrated better-than-expected efficacy with no serious adverse effects.
Patients with eczema, psoriasis, and sun-damaged skin showed measurable improvements. Mid- and high-dose groups experienced reduced senescent cell activity—25% of eczema participants reported significant itch relief, psoriasis patients saw 20% skin thickness reduction, and sun-damage cases exhibited increased collagen production.
The Phase 1 safety profile positions RLS-1496 as a potential breakthrough in longevity therapeutics. "These preliminary findings exceed our preclinical projections," noted researchers, highlighting the compound's dual action on cellular aging and tissue regeneration.
